OT mobile menu

Search form


Skin Cancer / Melanoma Targets

Skin Cancer / Melanoma Targets

Canadian researchers might have discovered why melanoma is more aggressive in men than women: decreased expression of a melanoma tumor suppressor gene on the sex chromosomes.

Scientists have found a way to detect earlier if Merkel cell carcinoma (MCC) is recurring in patients. They have published a paper in the journal Cancer demonstrating how an immune system marker may be able to outperform and supplement imaging studies for recurrence of MCC.

Researchers from Moffitt Cancer Center’s Integrated Mathematical Oncology (IMO) Department are overcoming some of the limitations of common preclinical experiments and clinical trials by studying cancer through mathematical modeling.

Immune checkpoint inhibitor-related neurotoxicities are more frequent in clinical practice than clinical trials.

A 54-year-old woman is found to have a skin lesion in the right arm. What is your diagnosis?

A novel immunotherapy antibody was safe and showed modest antitumor activity in a phase I clinical trial in advanced melanoma.

Objective tumor responses to pembrolizumab (Keytruda) and nivolumab (Opdivo) are associated with longer times between melanoma diagnosis and treatment.


Subscribe to Skin Cancer / Melanoma Targets on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.